- Previous Close
1.9908 - Open
2.1350 - Bid --
- Ask --
- Day's Range
2.0033 - 2.1350 - 52 Week Range
0.5424 - 3.1950 - Volume
1,751 - Avg. Volume
12,412 - Market Cap (intraday)
159.599M - Beta (5Y Monthly) 1.80
- PE Ratio (TTM)
-- - EPS (TTM)
-2.2930 - Earnings Date Nov 12, 2024 - Nov 18, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
www.herontx.com126
Full Time Employees
December 31
Fiscal Year Ends
--
Sector
--
Industry
Recent News: 0J4V.L
View MorePerformance Overview: 0J4V.L
Trailing total returns as of 9/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0J4V.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0J4V.L
View MoreValuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-35.29%
Return on Assets (ttm)
-8.58%
Return on Equity (ttm)
--
Revenue (ttm)
136.36M
Net Income Avi to Common (ttm)
-48.13M
Diluted EPS (ttm)
-2.2930
Balance Sheet and Cash Flow
Total Cash (mrq)
67.35M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
285k